Business Standard

Thursday, December 19, 2024 | 05:52 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Alembic Pharma Q1 PBT almost doubles to Rs 359 cr, income rises 40%

Company attributes the huge spike to a strong show in the international markets

Alembic Pharmaceuticals ups its US game plan, acquires Orit
Premium

While its international formulations business grew by 70 per cent to Rs 771 crore in Q1 of FY21, its US generics business rose 73 per cent to Rs 596 crore in the said quarter

Vinay Umarji Ahmedabad
Alembic Pharmaceuticals Limited (APL) has seen its consolidated profit before tax (PBT) grow by 91.40 per cent before exceptional items for the first quarter ended June 30, 2020 of financial year 2020-21. As against a consolidated PBT of Rs 187.82 crore in the corresponding Q1 in FY20, the same grew to Rs 359.50 crore in Q1 of FY21.

The company's consolidated total income rose by 40.89 per cent to stand at Rs 1,341.64 crore in Q1 of FY21 as compared to Rs 952.20 crore in Q1 of FY20. 

According to Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, despite challenging circumstances due to

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in